Search results
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions Latest version (submitted January 19, 2024) on ClinicalTrials.gov A study version is represented by a row in the table.
In June 2009, Feuerstein alleged the company was "seeking to divert investors' attention away from the delayed approval of Ampligen as a treatment for chronic fatigue syndrome" by issuing three press releases in seven days about research from 2007 into possible applications for Ampligen as a flu vaccine booster, in which Hemispherx stated that ...
11 lut 2024 · Ampligen is a mismatched, double-stranded RNA molecule with immunomodulatory and antiviral properties. In 2018, the FDA approved the compassionate care (expanded access) programme to allow for the treatment of up to 100 myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) patients at any one time at approved clinical infusion therapy sites.
In October 2020, AIM received Institutional Review Board approval for the expansion of the AMP-511 protocol to include patients previously diagnosed with SARS-CoV-2 following clearance of the virus, but who still demonstrate chronic fatigue-like symptoms (Long COVID).
Ampligen ® Has Significant Opportunity Across High-Value Multiple Disease Areas ~100,000 IV doses in humans, generally well-tolerated Positive Phase 3 data generated in U.S. in treatment of ME/CFS.
9 lut 2015 · Ampligen (rintatolimod) is a new drug in development for the treatment of a variety of chronic diseases and viral disorders. Ampligen information includes news, clinical trial results and side effects.
19 wrz 2024 · OCALA, Fla., Sept. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced positive preliminary data from the Phase 1b/2 study (“DURIPANC”) evaluating the...
